Zoledronic acid has no effect on knee pain or bone marrow lesions in knee OA after two years

(European League Against Rheumatism) The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2018) show that a one-yearly infusion of zoledronic acid (ZA) did not significantly reduce knee pain or bone marrow lesion (BML) size overall in knee osteoarthritis patients over two years. However, it may have symptomatic benefit in milder disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news